This Week in JAMA

Premium

In JAMA this week, Alberts et al. examine the effect of adding cetuximab to oxaliplatin, fluorouracil, and leucovorin on the survival of patients with resected stage III colon cancer. The team randomly assigned 2,686 patients to receive the standard leucovorin, fluorouracil, and oxaliplatin — or FOLFOX — adjuvant therapy either with or without cetuximab. After a median follow-up of 28 months, the team found no benefit of adding cetuximab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.